Multiple Myeloma

This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease...

全面介紹

Saved in:
書目詳細資料
格式: Online
語言:英语
出版: IntechOpen 2023
主題:
在線閱讀:ONIX_20231201_9781839686214_2104
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
_version_ 1869529050536476672
collection Directory of Open Access Books
description This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow–microenvironment interactions.
format Online
id doab-20.500.12854ir-130993
institution Directory of Open Access Books
language eng
publishDate 2023
publishDateRange 2023
publishDateSort 2023
publisher IntechOpen
publisherStr IntechOpen
record_format ojs
spelling doab-20.500.12854ir-1309932024-03-31T22:43:40Z Multiple Myeloma Fuchs, Ota daratumumab, tumor microenvironment, monoclonal antibodies, monoclonal antibody, overall survival, prognostic factors thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow–microenvironment interactions. 2023-12-01T18:38:20Z 2023-12-01T18:38:20Z 2021 book ONIX_20231201_9781839686214_2104 9781839686214 9781839686207 9781839686221 https://directory.doabooks.org/handle/20.500.12854/130993 eng image/jpeg n/a https://www.intechopen.com/books/9791 https://mts.intechopen.com/storage/books/9791/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/intechopen.87599 10.5772/intechopen.87599 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781839686214 9781839686207 9781839686221 IntechOpen 126 open access
spellingShingle daratumumab, tumor microenvironment, monoclonal antibodies, monoclonal antibody, overall survival, prognostic factors
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
Multiple Myeloma
title Multiple Myeloma
title_full Multiple Myeloma
title_fullStr Multiple Myeloma
title_full_unstemmed Multiple Myeloma
title_short Multiple Myeloma
title_sort multiple myeloma
topic daratumumab, tumor microenvironment, monoclonal antibodies, monoclonal antibody, overall survival, prognostic factors
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
topic_facet daratumumab, tumor microenvironment, monoclonal antibodies, monoclonal antibody, overall survival, prognostic factors
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
url ONIX_20231201_9781839686214_2104